Form 4: Centessa CPO Exercises Options, Sells Shares

Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, exercised stock options and subsequently sold 41,076 ordinary shares for a significant gain.

Summary

• Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals plc (CNTA), completed an option exercise and share sale transaction on March 26, 2026.
• Anderson acquired 41,076 Ordinary Shares by exercising stock options at a price of $8.01 per share.
• Immediately following the acquisition, Anderson sold all 41,076 Ordinary Shares at a weighted average price of $30.1242 per share.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 12, 2025.
• Following these transactions, Anderson beneficially owns 62,085 Ordinary Shares directly and retains 41,076 unexercised stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event for the company, as it represents a planned liquidity event for an executive, demonstrating personal financial management rather than a negative signal about the company's future. The executive still retains a significant number of shares and options.

Positives

• The Chief People Officer realized a substantial profit from exercising options at $8.01 and selling shares at a weighted average price of $30.1242.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than an immediate reaction to new information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage personal finances and diversify holdings. While a sale reduces insider ownership, the pre-planned nature often mitigates concerns about management's immediate view of the company's prospects.

Stakeholder Impact

• Shareholders: May observe a slight reduction in insider ownership, but the pre-planned nature of the sale under Rule 10b5-1 typically lessens negative interpretations regarding the company's future prospects.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

The filing details a routine, pre-planned insider transaction (option exercise and sale) by a Chief People Officer. This type of transaction, executed under a Rule 10b5-1 plan, is typically for personal financial management and diversification, not a signal of fundamental change in the company's prospects. It does not provide new information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1, Chief People Officer, Karen M. Anderson